DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/8xdjhz/investigation) has announced the addition of the "Investigation Report on China Oxiracetam Market, 2010-2019" report to their offering.
Oxiracetam, a derivative of pyrrolidone, was first synthesized by ISF in 1974. It is a nootropic drug whose oral preparation and injection entered the Italian market respectively in 1987 and 1990.
Oxiracetam develops fast after entering China, annual sales rising from less than 20 million in 2005 to 1.235 billion in 2014 and CAGR reaching up to 60% during the period of 2005- 2014. Oxiracetam enjoys a vast demand in China. Products from CSPC Ouyi Pharmaceutical Co., Ltd, Hunan Jianlang Pharmaceutical Co., Ltd, Harbin Medisan Pharmaceutical Co., Ltd and Guangdong SENCEE Pharmaceutical Co., Ltd all occupy certain share of the market, among which Guangdong SENCEE has the largest market share of 34.16% with sales revenue reaching up to CNY 422 million in 2014.
As the ageing of population becomes more and more serious in China, senile dementia increasingly becomes a severe social problem. The market size of oxiracetam in China is expected to keep growing in the next few years.
Key Topics Covered:
1 Related Concepts of Oxiracetam
2 Market Profile of Oxiracetam in China
3 Survey on Sales Status of Oxiracetam in China, 2010-2014
4 Survey on Market Share of Major Manufacturers of Oxiracetam in China, 2010-2014
5 Survey on Dosage Forms of Oxiracetam in China, 2010-2014
6 Reference Price of Oxiracetam in Chinese Hospitals in 2014
7 Major Manufacturers of Oxiracetam in the Chinese Market, 2010-2014
8 Market Outlook of Oxiracetam in China, 2015-2019
- CSPC Ouyi Pharmaceutical Co., Ltd
- Guangdong SENCEE Pharmaceutical Co., Ltd
- Harbin Medisan Pharmaceutical Co., Ltd
- Hunan Jianlang Pharmaceutical Co., Ltd
For more information visit http://www.researchandmarkets.com/research/8xdjhz/investigation